Sign in

    Miles Minter

    Partner and Equity Research Analyst at William Blair

    Myles Minter, Ph.D., is a Partner and Equity Research Analyst at William Blair, specializing in biotechnology equity research with a focus on central nervous system and neurobiology-driven drug development. He covers companies including Contineum Therapeutics, Axsome Therapeutics, Minerva Neurosciences, and has provided expert commentary on major industry acquisitions involving firms like Neurocrine Biosciences. Since joining William Blair in October 2017, following a postdoctoral appointment at the University of Chicago, Minter has initiated coverage on pivotal biotech companies and contributed to expanding the firm's sector expertise. He holds a Ph.D. in neuropharmacology and a Bachelor of Biomedical Science from the University of Melbourne, and is a registered securities professional, though specific FINRA registration numbers are not publicly listed.

    Miles Minter's questions to BIOGEN (BIIB) leadership

    Miles Minter's questions to BIOGEN (BIIB) leadership • Q2 2025

    Question

    Jake, on for Miles Minter at William Blair, asked about the selzartamab opportunity in antibody-mediated rejection (AMR), how Biogen models the market, and the influence of competitor data on expansion strategies.

    Answer

    CEO Christopher Viehbacher estimated the addressable AMR market at approximately $1.5 billion annually and expressed confidence that selzartamab is positioned to be first-to-market. Priya Singhal, EVP & Head of Development, added that they are expanding into a fourth indication, late MBI, a newly classified rejection phenotype which represents an additional 5,000-6,000 patients and augments the overall opportunity.

    Ask Fintool Equity Research AI